Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.93 [0.81, 1.06] | | < 1 | | 0% | 2 studies (2/-) | 87.2 % | some concern | not evaluable | moderate | crucial | - |
progression or deaths (PFS) | 1.56 [1.38, 1.78] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | important | - |
objective responses (ORR) | 0.50 [0.17, 1.47] | | > 1 | | 91% | 2 studies (2/-) | 10.6 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 0.34 [0.11, 1.06] | | < 1 | | 0% | 1 study (1/-) | 96.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.09 [0.06, 0.14] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 0.96 [0.19, 4.80] | | < 1 | | 0% | 1 study (1/-) | 52.0 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 0.19 [0.09, 0.38] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.15 [0.08, 0.30] | | < 1 | | 77% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 0.31 [0.21, 0.47] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 2.84 [0.29, 27.42] | | < 1 | | 0% | 1 study (1/-) | 18.6 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 0.55 [0.24, 1.28] | | < 1 | | 0% | 1 study (1/-) | 91.8 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Alopecia TRAE (grade 3-4) | 0.30 [0.03, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 83.5 % | some concern | not evaluable | moderate | non important | - |
Anaemia TRAE (grade 3-4) | 0.23 [0.04, 1.25] | | < 1 | | 83% | 2 studies (2/-) | 95.5 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 0.09 [0.01, 0.73] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | non important | - |
Blood creatinine increased TRAE (grade 3-4) | 0.96 [0.06, 15.44] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 0.16 [0.01, 3.11] | | < 1 | | 0% | 1 study (1/-) | 88.6 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.96 [0.02, 48.60] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.56 [0.03, 11.52] | | < 1 | | 71% | 2 studies (2/-) | 64.6 % | some concern | not evaluable | moderate | non important | - |
Diabetes TRAE (grade 3-4) | 0.94 [0.02, 47.47] | | < 1 | | 0% | 1 study (1/-) | 51.2 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.26 [0.08, 0.83] | | < 1 | | 1% | 2 studies (2/-) | 98.9 % | some concern | not evaluable | moderate | non important | - |
Dizziness TRAE (grade 3-4) | 0.48 [0.02, 14.35] | | < 1 | | 0% | 1 study (1/-) | 66.2 % | NA | not evaluable | | non important | - |
Dry skin TRAE (grade 3-4) | 0.96 [0.02, 48.60] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
Dysgeusia TRAE (grade 3-4) | 0.96 [0.02, 48.60] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.22 [0.03, 1.54] | | < 1 | | 68% | 2 studies (2/-) | 93.5 % | some concern | not evaluable | moderate | non important | - |
Hepatitis TRAE (grade 3-4) | 7.60 [0.40, 144.43] | | < 1 | | 0% | 1 study (1/-) | 9.1 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.94 [0.02, 47.47] | | < 1 | | 0% | 1 study (1/-) | 51.2 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 3.77 [0.17, 84.06] | | < 1 | | 0% | 1 study (1/-) | 20.4 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 1.41 [0.11, 18.47] | | < 1 | | 0% | 2 studies (2/-) | 39.6 % | some concern | not evaluable | moderate | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.47 [0.02, 14.02] | | < 1 | | 0% | 1 study (1/-) | 66.7 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.48 [0.02, 14.35] | | < 1 | | 0% | 1 study (1/-) | 66.2 % | NA | not evaluable | | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.03 [0.00, 0.51] | | < 1 | | 0% | 1 study (1/-) | 99.2 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.14 [0.02, 1.23] | | < 1 | | 49% | 2 studies (2/-) | 96.1 % | some concern | not evaluable | moderate | non important | - |
Neutropenia TRAE (grade 3-4) | 0.01 [0.00, 0.06] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.06 [0.00, 1.02] | | < 1 | | 0% | 1 study (1/-) | 97.3 % | NA | not evaluable | | non important | - |
Pancreatitis TRAE (grade 3-4) | 0.47 [0.02, 14.02] | | < 1 | | 0% | 1 study (1/-) | 66.7 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.19 [0.02, 2.03] | | < 1 | | 3% | 2 studies (2/-) | 91.4 % | some concern | not evaluable | moderate | non important | - |
Pneumonitis TRAE (grade 3-4) | 3.77 [0.17, 84.06] | | < 1 | | 0% | 1 study (1/-) | 20.4 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.96 [0.02, 48.60] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.96 [0.02, 48.60] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
Severe skin reaction TRAE (grade 3-4) | 1.88 [0.06, 56.28] | | < 1 | | 0% | 1 study (1/-) | 36.0 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 0.05 [0.00, 0.89] | | < 1 | | 0% | 1 study (1/-) | 97.8 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.08 [0.00, 1.41] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.03 [0.00, 0.55] | | < 1 | | 0% | 1 study (1/-) | 99.1 % | NA | not evaluable | | non important | - |
Weight decreased TRAE (grade 3-4) | 0.48 [0.02, 14.35] | | < 1 | | 0% | 1 study (1/-) | 66.2 % | NA | not evaluable | | non important | - |